2.18
-0.05(-2.24%)
Currency In USD
| Previous Close | 2.23 |
| Open | 2.16 |
| Day High | 2.2 |
| Day Low | 2.09 |
| 52-Week High | 3.95 |
| 52-Week Low | 1.09 |
| Volume | 1.35M |
| Average Volume | 1.57M |
| Market Cap | 155.17M |
| PE | -1.31 |
| EPS | -1.67 |
| Moving Average 50 Days | 2.33 |
| Moving Average 200 Days | 2.09 |
| Change | -0.05 |
If you invested $1000 in C4 Therapeutics, Inc. (CCCC) since IPO date, it would be worth $85.52 as of January 21, 2026 at a share price of $2.18. Whereas If you bought $1000 worth of C4 Therapeutics, Inc. (CCCC) shares 5 years ago, it would be worth $59.13 as of January 21, 2026 at a share price of $2.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways
GlobeNewswire Inc.
Jan 14, 2026 12:00 PM GMT
Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026 Internal Discovery Strategy Progressing Efforts Focused
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
GlobeNewswire Inc.
Nov 25, 2025 12:00 PM GMT
WATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will partici
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
GlobeNewswire Inc.
Oct 16, 2025 11:08 AM GMT
$125 Million in Upfront Proceeds Expected to Fund Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 Trial in Combination with Dexamethasone and Phase 1b Trial in Combination with Elranatamab Potential to Earn up